Recent News for PSNL - Personalis, Inc.

Date Title
Sep 12 Personalis Appoints Karin Eastham to Its Board of Directors
Sep 9 Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
Aug 26 Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference
Aug 23 Personalis: Potential Growth Champion Has Much To Prove
Aug 15 61 Biggest Movers From Yesterday
Aug 14 Personalis, Inc. (PSNL) CEO John West on Q2 2019 Results - Earnings Call Transcript
Aug 13 Personalis EPS misses by $0.61, beats on revenue
Aug 13 Personalis Reports Second Quarter 2019 Financial Results
Aug 8 90 Biggest Movers From Yesterday
Aug 7 Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study
Aug 1 Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications
Jul 30 Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019
Jul 26 Stocks That Managed to Breach 52-Week Lows Friday
Jul 18 2 Small-Cap Biotech IPOs You Should Know About
Jul 15 Wells sees 33% upside in Gilead in premarket analyst action
Jul 13 Stocks To Watch: Prime Day And FAANGs Out In DC
Jul 11 Why Personalis Is Helping Make Cancer Therapy Personal For Each Patient
Jul 6 3 Top Stocks That Aren't On Wall Street's Radar
Jul 3 The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief
Jun 24 Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option
Jun 20 Personalis: Potential Personal Genomics Growth Champion
Jun 20 Personalis IPO: What You Need To Know
Jun 20 Personalis prices IPO at $17
Jun 20 Personalis Prices Initial Public Offering of Common Stock
Jun 17 IPO Outlook For The Week: Biotechs And A Grocery Outlet
Back to the Main PSNL Page...